Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;87(1):27-31.
doi: 10.1038/clpt.2009.179.

Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process

L Liberti  1 , A Breckenridge, H G Eichler, R Peterson, N McAuslane, S Walker
Affiliations

Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process

L Liberti et al. Clin Pharmacol Ther. 2010 Jan.

Abstract

Ideally, well-designed global pharmaceutical development programs that include simultaneous submissions to multiple regulatory agencies can result in predictable regulatory approvals and expedited access to medicines for all patients. The workshops described herein investigated current trends in development and submission strategies along with regulatory review performance data in order to consider whether barriers to predictable expedited approval outcomes can be overcome through innovative clinical development approaches and a better understanding of review processes and procedures, particularly as these relate to the assessment of a product's risk-benefit profile.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • European regulation on orphan medicinal products: 10 years of experience and future perspectives.
    Committee for Orphan Medicinal Products and the European Medicines; Westermark K, Holm BB, Söderholm M, Llinares-Garcia J, Rivière F, Aarum S, Butlen-Ducuing F, Tsigkos S, Wilk-Kachlicka A, N'Diamoi C, Borvendég J, Lyons D, Sepodes B, Bloechl-Daum B, Lhoir A, Todorova M, Kkolos I, Kubáčková K, Bosch-Traberg H, Tillmann V, Saano V, Héron E, Elbers R, Siouti M, Eggenhofer J, Salmon P, Clementi M, Krieviņš D, Matulevičiene A, Metz H, Vincenti AC, Voordouw A, Dembowska-Bagińska B, Nunes AC, Saleh FM, Foltánová T, Možina M, Torrent i Farnell J, Beerman B, Mariz S, Evers MP, Greene L, Thorsteinsson S, Gramstad L, Mavris M, Bignami F, Lorence A, Belorgey C. Committee for Orphan Medicinal Products and the European Medicines, et al. Nat Rev Drug Discov. 2011 May;10(5):341-9. doi: 10.1038/nrd3445. Nat Rev Drug Discov. 2011. PMID: 21532564 Review.
  • Vascularization in bone tissue engineering constructs.
    Mercado-Pagán ÁE, Stahl AM, Shanjani Y, Yang Y. Mercado-Pagán ÁE, et al. Ann Biomed Eng. 2015 Mar;43(3):718-29. doi: 10.1007/s10439-015-1253-3. Epub 2015 Jan 24. Ann Biomed Eng. 2015. PMID: 25616591 Free PMC article. Review.
  • Suitability of paediatric legislation beyond the USA and Europe: a qualitative study on access to paediatric medicines.
    Volodina A, Jahn A, Jahn R. Volodina A, et al. BMJ Public Health. 2024 Feb 7;2(1):e000264. doi: 10.1136/bmjph-2023-000264. eCollection 2024 Jun. BMJ Public Health. 2024. PMID: 40018188 Free PMC article.
  • BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
    Davit BM, Kanfer I, Tsang YC, Cardot JM. Davit BM, et al. AAPS J. 2016 May;18(3):612-8. doi: 10.1208/s12248-016-9877-2. Epub 2016 Mar 4. AAPS J. 2016. PMID: 26943914 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources